Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes.
D000995:Antitubercular Agents / Q000494:pharmacology* / Q000627:therapeutic use; D003906:Developing Countries; D024881:Drug Resistance, Bacterial; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology; D008297:Male; D008826:Microbial Sensitivity Tests; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000302:isolation & purification; D015995:Prevalence; D012008:Recurrence; D012042:Registries; D012189:Retrospective Studies; D012293:Rifampin / Q000494:pharmacology; D012307:Risk Factors; D013183:Sputum / Q000382:microbiology; D013785:Thailand / Q000453:epidemiology; D016896:Treatment Outcome; D014376:Tuberculosis / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology
D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin